Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Stock Has Consensus Price Target of $28.38

Key Points

• Analyst sentiment is mixed: Seven brokerages rate Kestra Medical Technologies “Hold” on average, with four buys, two holds, and one sell. The consensus 12-month price target is $28.38 versus a recent price of $27.11.
• Recent results fell short of expectations: Kestra reported quarterly EPS of negative $0.75, missing the consensus estimate of negative $0.61, on revenue of $30.97 million. Analysts expect a full-year loss of approximately $2.45 per share.
• Insiders have been selling shares: Company insiders sold 246,928 shares worth roughly $6.0 million over the past 90 days, although some sales were made to cover tax withholding obligations tied to equity awards.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus recommendation of "Hold" from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $28.38.

Several equities analysts have recently weighed in on KMTS shares. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 16th. Oppenheimer began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a "market perform" rating on the stock. Wall Street Zen cut Kestra Medical Technologies from a "hold" rating to a "sell" rating in a report on Saturday, September 12th. Finally, JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an "overweight" rating and a $30.00 price objective on the stock.

Kestra Medical Technologies Stock Down 4.2%

NASDAQ KMTS opened at $27.11 on Friday. The business has a fifty day moving average price of $25.70 and a 200 day moving average price of $22.99. Kestra Medical Technologies has a one year low of $17.34 and a one year high of $30.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.69 and a current ratio of 4.69. The company has a market cap of $1.61 billion, a P/E ratio of -10.15 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%.The business had revenue of $30.97 million for the quarter. Research analysts anticipate that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Kevin Reilly sold 2,932 shares of Kestra Medical Technologies stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total transaction of $73,681.16. Following the transaction, the director owned 5,368 shares in the company, valued at $134,897.84. The trade was a 35.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Raymond W. Cohen sold 3,330 shares of the firm's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $29.28, for a total transaction of $97,502.40. Following the sale, the director owned 54,790 shares of the company's stock, valued at approximately $1,604,251.20. The trade was a 5.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 246,928 shares of company stock worth $5,997,473. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in KMTS. The Manufacturers Life Insurance Company raised its position in Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company's stock valued at $1,844,000 after purchasing an additional 5,731 shares during the period. California State Teachers Retirement System grew its holdings in shares of Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company's stock worth $555,000 after purchasing an additional 7,844 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $431,000. Bank of New York Mellon Corp increased its position in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock worth $1,397,000 after purchasing an additional 22,471 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies in the 1st quarter valued at about $603,000.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company's primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient's heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.